Orap

Orap was FDA approved for treating psychosis and is also used as an antipsychotic. In September 1999, new Orap warnings were issued because of the potentially fatal electrical disturbances of the heart. When Orap was first approved, the treatment option was not supposed to be used in patients that did not first try alternate choices. The Orap warning also stated that combining Orap with other therapies, because of the prolonged QT interval it caused, could have additive effects if the other drugs also prolonged the QT interval.

All antipsychotics have been linked to Tardive Dyskinesia. With the growing number of prescription choices available, Tardive Dyskinesia is occurring at a greater frequency, but Orap and other antipsychotic patients are still very unaware of these risks. Many critics of Orap and other antipsychotic drugs think patients are not being adequately warned about Tardive Dyskinesia occurrences because so little is still known about it.
Antipsychotic effects were initially thought to be safe for schizophrenia treatment because of the few side effects. Orap’s drug interactions have been deadly and very serious. For more information on Orap contact us to confer with an Orap lawyer.